Bausch + Lomb Corp Earnings
Bausch + Lomb Corporation, a prominent global eye health company, recently disclosed its financial results for the fourth quarter and full year of 2024. The results highlighted the company's robust performance across its various business segments, demonstrating significant growth and resilience amid challenging economic conditions.
Bausch + Lomb Corp Results
For the fourth quarter of 2024, Bausch + Lomb reported total revenue of $1.280 billion, representing a 9% increase from the same period in 2023. The company experienced a GAAP net loss attributable to Bausch + Lomb Corporation of $3 million. Despite this loss, the adjusted EBITDA, excluding acquired in-process research and development (IPR&D), stood at $259 million.
In full-year terms, the company reported total revenue of $4.791 billion, an impressive growth of 16% compared to 2023. However, the GAAP net loss was $317 million for the year. Adjusted EBITDA, excluding acquired IPR&D, reached $878 million. Here's a detailed financial comparison:
| Metric | Q4 2024 | Q4 2023 | % Change | FY 2024 | FY 2023 | % Change |
|---|---|---|---|---|---|---|
| Total Revenue | $1.280B | $1.173B | 9% | $4.791B | $4.146B | 16% |
| GAAP Net Loss Attributable | $3M | $54M | -94% | $317M | $260M | 22% |
| Adjusted EBITDA (excl. Acquired IPR&D) | $259M | $231M | 12% | $878M | $738M | 19% |
Revenue Breakdown
The company's revenue growth was underpinned by a strong performance across its major segments. Here's how each segment contributed:
Fourth-Quarter 2024 Revenue Performance
| Segment | Q4 2024 Revenue | Q4 2023 Revenue | % Change |
|---|---|---|---|
| Vision Care | $723M | $662M | 9% |
| Surgical | $231M | $204M | 13% |
| Pharmaceuticals | $326M | $307M | 6% |
Full-Year 2024 Revenue Performance
| Segment | FY 2024 Revenue | FY 2023 Revenue | % Change |
|---|---|---|---|
| Vision Care | $2.739B | $2.543B | 8% |
| Surgical | $843M | $767M | 10% |
| Pharmaceuticals | $1.209B | $836M | 45% |
In-Depth Segment Analysis
-
Vision Care : Revenue for this segment grew by 9% in the fourth quarter and 8% over the full year. This growth was primarily driven by increased consumer demand for LUMIFY®, over-the-counter dry eye products, and eye vitamins. In the contact lens division, products such as Daily SiHy lenses and Bausch + Lomb ULTRA® experienced significant growth.
-
Surgical : The surgical segment saw a 13% increase in revenue for the fourth quarter and achieved a 10% rise for the full year. The demand for consumables, equipment, and implantables, including a robust performance from the premium IOL portfolio, contributed to this growth.
-
Pharmaceuticals : The most significant surge was seen in the Pharmaceuticals segment, which posted a 45% growth over the year, bolstered by the launch of MIEBO® and incremental sales from the XIIDRA® acquisition. The U.S. Generics and International Pharmaceuticals sectors also demonstrated substantial revenue enhancement.
Key Developments
During the quarter, Bausch + Lomb aimed at diversifying and expanding its product pipeline. The company achieved notable advancements, including:
- Strong execution in dry eye portfolio, nearing $1 billion in annual revenue.
- Double-digit growth in the contact lens sector.
- Expansion of its surgical product categories.
- Continued enhancement and diversification of the R&D pipeline with strategic investments, including acquiring Elios Vision.
Comments from Company Officers
Brent Saunders, Chairman and CEO of Bausch + Lomb, underscored the company’s strategic growth initiatives by stating, "Underpinning our recent success is a commitment to long-term, profitable growth. Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for patients across the spectrum of eye health needs." This statement illuminates the company’s commitment to innovation and quality improvement in its offerings.
Dividends and Share Repurchases
In this fiscal period, the company did not announce changes regarding dividend policy or any active share repurchase programs. The management decisions were primarily focused on reinvesting within the company to fuel further growth and expansion.
Bausch + Lomb Corp Stock Forecast
Based on the latest quarter's performance and strategic developments, Bausch + Lomb's stock is expected to show a mixed outlook in the near term. As of the last available data, stocks experienced a price change, moving to approximately -0.37% after the financial event. With a current market cap of $5.19 billion, the company's stock price could see a range of movements.
-
High Projection : Given the strong performance across the segments, especially with pharmaceuticals, a high projection for the stock might aim for an upper reach if growth trends continue and market conditions remain favorable.
-
Low Projection : Should macroeconomic conditions impose constraints, or the company face unforeseen challenges in its portfolio expansion, stocks could potentially settle closer to lower ends of projections in the short-term.
Overall, Bausch + Lomb's strategic direction and robust performance in key sectors make it an interesting prospect for investors focusing on long-term value and growth in the eye health industry.
